11 Biotech Bets For 2012
By James Stocklasar Thomas Jr. : Mid-range biotechs like the ones mentioned in here are the most tempting buyout targets. They are Questcor-like ( QCOR ) in their forward vision to win enviable investment from the major institutions. Questcor recently exploded from around $26/share to over ...
Read the rest of this article on Healthcare Sector and Stocks Analysis from Seeking Alpha
Related Videos
-
No Sign of Slowdown in Biotech M&AHigh levels of merger and acquisition activity will be the big theme of year for biotech , says Morningstar's Lauren Migliore.
-
Our Top Five Biotech Takeout PicksHealth-care analyst Lauren Migliore looks at what makes a biotech firm a likely takeout candidate and reveals our top five biotech M&A picks for 2010.
-
Our Top Five Biotech Acquisition CandidatesM&A activity grew in 2010, and we expect deal volume to remain strong in 2011.
-
Biotech and Pharma Still Look CheapDodge & Cox's Diana Strandberg and Charles Pohl discuss why the pharma industry looks like one of the most compelling places to invest today.